No Data
Zhejiang Medicine (SHSE:600216) Shareholders YoY Returns Are Lagging the Company's 181% One-year Earnings Growth
zhejiang medicine (600216.SH): folic acid is not included in the main products.
Gelonghui November 22nd, zhejiang medicine (600216.SH) stated on the investor interaction platform that folic acid is not included in the company's main products.
Debon Securities: The third quarter of 2024 may mark the bottom of chemical profits, with a turning point in the capacity cycle.
In the third quarter, the industry gross margin was 16.22%, -0.35pct year-on-year, -1.12pct quarter-on-quarter; net income attributable to mother was 5.01%, -0.34% year-on-year, -1.29pct quarter-on-quarter.
Zhejiang Medicine Co., Ltd. (SHSE:600216) Might Not Be As Mispriced As It Looks
Zhejiang Medicine Q3 Profit Surges 1,738%, Revenue Climbs 40%
Zhejiang Pharmaceutical Report for the Third Quarter of 2024
The Three-year Shareholder Returns and Company Earnings Persist Lower as Zhejiang Medicine (SHSE:600216) Stock Falls a Further 4.0% in Past Week
